In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant.

Abstract

PURPOSE To study the use of fibrin sealant as a drug delivery system for the sustained transscleral delivery of dexamethasone and methotrexate. METHODS Scleral sections excised from moist-chamber-stored human globes were mounted in a perfusion chamber. Dexamethasone-fluorescein or methotrexate-fluorescein in either fibrin sealant or balanced salt solution (BSS) was applied to the episcleral surface. BSS was perfused to the choroidal side, fluorescence was measured in perfusate fractions, and an apparent scleral permeability P(A) was calculated for each solute-vehicle combination. RESULTS P(A) for both compounds was significantly lower with fibrin sealant delivery compared to delivery in BSS (p < 0.001). However, the fibrin sealant vehicle provided a more sustained release of both drugs through 24 hr. CONCLUSIONS Incorporating dexamethasone and methotrexate into a fibrin sealant provided a more gradual drug delivery and a more uniform delivery compared to dissolving these drugs in BSS. Fibrin sealant could be useful for transscleral delivery for posterior segment disease.

Statistics

010002000'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

2,631 Citations

Semantic Scholar estimates that this publication has 2,631 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Cruysberg2005InVS, title={In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant.}, author={Lars P. J. Cruysberg and Rudy Nuijts and Jake A Gilbert and Dayle H. Geroski and Fred Hendrikse and Henry F. Francis Edelhauser}, journal={Current eye research}, year={2005}, volume={30 8}, pages={653-60} }